Equities

Shanghai Junshi Biosciences Co Ltd

Shanghai Junshi Biosciences Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)14.10
  • Today's Change0.36 / 2.62%
  • Shares traded1.81m
  • 1 Year change-37.61%
  • Beta0.8794
Data delayed at least 15 minutes, as of Nov 08 2024 08:08 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments3,7785,9973,505
Total Receivables, Net6133201,423
Total Inventory538599485
Prepaid expenses245240397
Other current assets, total3764922
Total current assets5,5507,2055,832
Property, plant & equipment, net4,2533,2783,070
Goodwill, net------
Intangibles, net1349940
Long term investments1,1621,4181,502
Note receivable - long term5842154
Other long term assets------
Total assets11,36212,57611,051
LIABILITIES
Accounts payable247282196
Accrued expenses1,395917671
Notes payable/short-term debt000
Current portion long-term debt/capital leases57543545
Other current liabilities, total2581401,105
Total current liabilities2,4751,7742,017
Total long term debt1,213886583
Total debt1,7891,322628
Deferred income tax------
Minority interest169293371
Other liabilities, total334122119
Total liabilities4,1923,0753,090
SHAREHOLDERS EQUITY
Common stock986983911
Additional paid-in capital14,79714,53210,672
Retained earnings (accumulated deficit)(8442)(5945)(3622)
Treasury stock - common(27)----
Unrealized gain (loss)(181)(97)19
Other equity, total3828(19)
Total equity7,1719,5017,961
Total liabilities & shareholders' equity11,36212,57611,051
Total common shares outstanding985983911
Treasury shares - common primary issue--00
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.